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ABSTRACT Fas is a cell surface death receptor that
regulates peripheral tolerance and lymphoid homeostasis. In
many pathologic conditions, ectopic Fas activation mediates
tissue destruction. Several proteins that can bind to the
cytoplasmic death domain of Fas have been implicated in Fas
signal transduction. Here we show that FADD, which couples
Fas to pro-caspase-8, and, Daxx, which couples Fas to the Jun
N-terminal kinase pathway, bind independently to the Fas
death domain. We have isolated a death domain mutant,
termed FasD, that selectively binds Daxx but not FADD. In
tranfected tissue culture cells, FasD activated Jun N-terminal
kinase normally but was impaired in cell death induction.
These results suggest that FADD and Daxx activate two
independent pathways downstream of Fas and confirm the
essential role of FADD binding in apoptosis induction.
Members of the tumor necrosis factor receptor (TNFR)
superfamily are cell surface cytokine receptors that control
critical cell fate decisions such as proliferation, differentiation,
and apoptosis. The TNFR superfamily includes the B cell
costimulatory receptor CD40, receptors for the inflammatory
cytokine TNF-a, and a growing family of death receptors (1).
The prototype of the death receptors is Fas (also named CD95
and APO-1), a ubiquitously expressed receptor for a cytotoxic
ligand (FasL) normally expressed on activated T cells and
certain immune privileged sites (2, 3). Fas has an essential role
in maintaining homeostasis in the immune system, and both
deficient or excess Fas signaling can cause human diseases.
Following repeated T cell activation, T cells express FasL and
commit autocrine suicide, a process termed activation-induced
cell death that is important for normal restraint of the immune
response (4). Depending on the signal from the B cell antigen
receptor, Fas induces either apoptosis or proliferation of B
cells in vivo (5). Mice and human deficient in Fas function
develop massive lymphadenopathy and are prone to develop
severe autoimmune disease (2). On the other hand, ectopic
activation of FasL–Fas interaction by cytokines or drugs
underlies tissue destruction in fulminant hepatitis, autoim-
mune Hashimoto’s thyroiditis and type I diabetes, and toxic
epidermal necrolysis (6–9). In addition, as a result of Fas-
mediated neutrophil activation, FasL causes potent inflamma-
tory responses in many tissues (10).
The signal transduction pathways downstream of Fas have
been studied with rapid progress over the last several years.
The cytoplasmic domain of Fas has no enzymatic activity but
contains a protein-interaction motif termed the ‘‘death do-
main.’’ An adapter protein, termed FADD or Mort1, binds to
the Fas death domain and recruits pro-caspase-8, the zymogen
form of an apical cell death protease (11–12). Fas crosslinking
by the trimeric FasL or agonisitic antibody induces the prox-
imity of pro-caspase-8 molecules, allowing them to cleave one
another and become activated (13–16). Active caspase-8 can
then cleave other pro-caspases and activate a caspase cascade,
leading to cell death (17). Several viral and cellular pro-
caspase-8 like proteins, termed FLIPs (18), contain FADD-
interacting DED motifs but inactive protease domains, and
they are potent inhibitors of Fas-induced cell death in tissue
culture cells and in primary lymphocytes (19–20). An alternate
pathway involves the Fas-binding protein Daxx (21). On Fas
activation, Daxx interacts with and activates a mitogen-
activated protein kinase kinase kinase termed ASK1 (Apo-
ptosis Signal-regulating Kinase 1), leading to the activation of
the Jun N-terminal kinase (JNK) and p38 MAP kinase path-
ways (22). JNK and p38 kinase cascades are also activated by
many kinds of stress, and they culminate in the phosphoryla-
tion and activation of transcription factors such as AP-1,
ATF-2, and other cellular targets (23). JNK has been previ-
ously implicated in activating apoptosis in vitro and in vivo (24,
25), but its functional role in death-receptor signaling, as
assayed by expressing dominant negative proteins, has been
controversial (21, 26–29). JNK activation has also been re-
ported to occur downstream of caspases based on studies with
caspase inhibitors (28, 30), but its functional significance and
relationship to Daxx-mediated JNK activation are unclear.
The in vivo role of the Fas-FADD-pro-caspase-8 axis has
been bolstered by the generation of mice deficient for FADD
or overexpressing the FADD death domain (1). FADD-
deficient mice are embryonic lethal due to cardiac defects (31).
FADD2/2 embryonic stem (ES) cells are resistant to Fas,
TNF-a, and some (but not all) death receptors (31). Similarly,
Casp8-deficient embryos are prenatally lethal, and Casp82/2
fibroblasts are resistant to death induction by Fas, TNF-a, and
the death receptor family member DR3 (32). These results
strongly suggest that FADD-mediated caspase activation is
essential for Fas-induced apoptosis, but possible secondary
effects of FADD or caspase-8 deficiency could not be ruled
out. For example, FADD-deficient T cells do not proliferate
(33), making it impossible to test the role of FADD in the
natural context of activation-induced cell death.
In this report, we have used a complementary approach to
dissect Fas signaling. We demonstrate that FADD and Daxx
bind independently to Fas and identify a Fas mutant that
selectively fails to bind FADD. This mutant is substantially
impaired in apoptosis induction but is fully capable of activat-
ing JNK, illustrating the two distinct pathways mediated by
FADD and Daxx downstream of Fas.
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MATERIALS AND METHODS
Reagents and Cell Lines. Anti-murine Fas Jo2 antibody
(PharMingen) and anti-Flag mAb M2 (Kodak/IBI) were ob-
tained from the indicated sources. HeLa and 293 cells were
obtained originally from American Type Culture Collection.
Plasmid Construction. Glutathione S-transferase (GST)
constructs were made in pGEX vector (Amersham Pharma-
cia). pEBB-Myc-Fas and pEBB-Myc-FasD were each con-
structed with a Myc epitope tag inserted after the leader
sequence by using PCR with Pfu polymerase (Stratagene).
Each construct was confirmed by partial DNA sequencing and
by immunoblot analysis.
In Vitro Binding Assays. Glutathione S-transferase (GST)
fusions were purified as described (34). 35S-labeled proteins
were made with TNT Reticulocyte Lysate System (Promega)
from pRK5-FADD(80–205) (35) or pRSET-H6T-DaxxC (21).
The in vitro translation (IVT) of FADD(80–205) gave approx-
imately 100-fold more protein than that of DaxxC. 35S-labeled
proteins were incubated with 2 mg of each GST fusion protein
in 0.1 ml of modified E1A buffer (36) with 50 mM NaCl and
10% glycerol for 1 to 2 hours, washed three times, and analyzed
by using SDS/PAGE and autoradiography. Recombinant pu-
rified hFADD(95–208) was the gift of B. Huang and S. Fesik
(Abbott).
Apoptosis Assay. Transient transfection and apoptotic mor-
phology assay in HeLa cells were performed as described (21).
Specific apoptosis was calculated as the percentage of blue
cells with apoptotic morphology in each experimental condi-
tion minus the percentage of blue cells with apoptotic mor-
phology in pEBB vector-transfected cells. pEBB vector control
transfection was always done in parallel and had '5% or less
apoptotic cells.
JNK Activation Assay. Twenty four hours after transient
transfection, cells were treated with 0.5 mg/ml Jo2 antibody for 30
min. Flag-JNK1 was immunoprecipitated with anti-Flag anti-
body, and in vitro kinase assay with 1 mg of GST-cJun(1–79) was
performed as described (21).
RESULTS
Daxx and FADD Bind Independently to Fas. Several pro-
teins, including FADD and Daxx, have been reported to bind
to the death domain of Fas (1). FADD binding to Fas occurs
via homotypic interactions of their death domains, whereas
Daxx binds to Fas death domain via a novel motif, termed
DaxxC, that has no sequence similarity to death domains (37,
38, 21). To understand how these interactions affect one
another, we carried out binding studies in vitro with these three
protein domains. In vitro translated, 35S-labeled DaxxC and the
FADD death domain [FADD(80–205)] bound to the immo-
bilized GST fusion protein of Fas intracellular tail (GST-
FasIC) (Fig. 1A, lane 1). Addition of cold DaxxC or FADD
death domain to the binding reaction competed with binding
of the homologous 35S-labeled protein, but no cross competi-
tion was observed (Fig. 1 A, lanes 2–7). This result suggests that
Daxx and FADD do not compete for the same binding site on
Fas. Next, to test whether the Daxx and FADD bindings are
cooperative, 35S-labeled DaxxC or FADD(80–205) was ti-
trated into the binding reaction in the absence or presence of
a saturating amount of the heterologous cold protein. The
amount of cold proteins used was sufficient to completely
block by competition binding of the homologous material (as
determined in Fig. 1 A), but they did not affect the binding
curve of the heterologous 35S-labeled proteins (Fig. 1B).
Because Daxx and FADD binding to Fas is neither competitive
nor cooperative, these results indicate that Daxx and FADD
bind independently to Fas.
Identification of a Fas Mutant That Selectively Fails to Bind
FADD. The independent binding of FADD and Daxx to Fas
predicts that it should be possible to isolate Fas mutants that
selectively abrogate one interaction without affecting the
other. The N-terminal boundary of the Fas death domain has
been assigned based on sequence similarity to the death
domain of TNF receptor 1 (39, 40), and the C-terminal
boundary has been determined experimentally by the cyto-
toxic activities of Fas mutants bearing progressive truncations
from the C terminus (39). We noticed that particular N-
terminal fusions of the Fas death domain exhibited differential
binding properties for Daxx and FADD. These differences
were localized to nine amino acids at the N terminus of the Fas
death domain and we therefore compared an intact death
domain (FasIC) to one lacking the first nine amino acids
(192–200; FasD) (Fig. 2A). As shown previously, 35S-labeled
DaxxC and FADD(80–205) bound specifically to GST-FasIC
but not GST (Fig. 2B). GST-FasD bound specifically to DaxxC
as well as it did to GST-FasIC but did not bind detectably to
FADD(80–205). Previous structural studies revealed that the
Fas death domain consists of six antiparallel amphipathic
helices; charged residues in helix 2 and 3 are thought to
mediate electrostatic interactions with FADD (42). Because
amino acids 192–200 are positioned far away from this region,
the defect of FasD in FADD binding may result from allosteric
effects. The ability of FasD to selectively bind Daxx but not
FADD confirms that Daxx and FADD bind independently to
Fas and provides a potentially useful tool to dissect Fas
signaling.
JNK Activation and Apoptosis by FasD. Based on overex-
pression experiments with wild-type and dominant negative
proteins, we previously suggested that Daxx is both sufficient
and necessary to mediate JNK activation by Fas in human
embryonic kidney 293 cells (21). Fas also activates JNK in
HeLa cells by a FADD-independent mechanism (43). To test
how the FasD mutation may affect Fas signaling, we con-
structed full-length murine Fas and FasD with a Myc-epitope
FIG. 1. Independent binding of DaxxC and FADD(80–205) to Fas.
(A) Binding of in vitro-translated [35S]DaxxC and FADD(80–205) to
GST-FasIC. [35S]DaxxC (5 ml) and [35S]FADD(80–205) (0.1 ml) IVT
reactions were added in all lanes. Lanes 2, 3, and 4 contained 5, 10, or
20 ml of IVT nonradioactive DaxxC; lanes 5, 6, and 7 contained 0.5,
2, or 5 mg of recombinant purified hFADD(95–208). (B) Lack of
cooperative binding of DaxxC and FADD(80–205) to GST-FasIC.
Upper, [35S]FADD(80–205) IVT reaction (0.1 ml in lanes 1 and 4; 0.3
ml in lanes 2 and 5; 1.0 ml in lanes 3 and 6) were incubated with
GST-FasIC in the absence (lanes 1–3) or presence (lanes 4–6) of 20
ml of nonradioactive IVT DaxxC. Lower, [35S]DaxxC IVT reaction (2
ml in lanes 1 and 4; 5 ml in lanes 2 and 5; 10 ml in lanes 3 and 6) were
incubated with GST-FasIC in the absence (lanes 1–3) or presence
(lanes 4–6) of 5 mg of recombinant purified hFADD(95–208). Posi-
tions of molecular weight standards (in kDa) are shown at right.
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tag on the N-terminal extracellular domain. Myc-Fas and
Myc-FasD were equivalently expressed after transient trans-
fection into 293 cells; both proteins migrated as a series of
bands on SDS/PAGE gels apparently because of glycosylation
(Fig. 3A). Fluorescence-activated cell sorting indicated that
both Fas proteins were present on the cell surface (data not
shown). Importantly, Myc-FasD activated JNK as well as
Myc-Fas as determined by in vitro kinase assays (Fig. 3B).
Coexpression of either FADD(80–205) or DaxxC with Fas
was previously reported to inhibit Fas killing in HeLa cells
(21), implying that both FADD and Daxx pathways were
required for apoptosis. Expression of Myc-Fas in HeLa cells
potently caused apoptosis in the presence of anti-mouse Fas
antibody Jo2 in a dose-dependent manner (Fig. 4A). Strikingly,
Myc-FasD did not cause appreciable cell death at 24 hours
after transfection. At 48 hours after transfection, there was
significant apoptosis in cells expressing Myc-FasD compared
with vector transfected cells, but the level of apoptosis was still
less than that caused by Myc-Fas (Fig. 4B). The apoptosis at 48
hours occurred in the absence of Jo2, which is likely the result
of the known propensity of Fas death domain at higher
concentrations to self-associate and initate signaling (44). The
complete loss of cell killing at 24 hours (but efficient killing at
48 hours) by Myc-FasD suggests that Fas can activate two
pathways for cell killing and that FADD binding is essential for
the direct initiation of apoptosis. FADD overexpression can
activate caspase-8 and quickly engage the apoptotic caspase
cascade (1). Killing by Myc-FasD may be relatively slow
because the Daxx pathway activates JNK and presumably
transcription, which then indirectly activates apoptosis. We
previously showed that expression of ASK1, a mitogen-
activated protein kinase kinase kinase activated by Daxx, does
not induce apoptosis in normal serum conditions, but coex-
pression with an activated allele of Daxx causes synergistic cell
killing (22). We hypothesized that because FasD binds Daxx
and presumably activates it, FasD should be able to activate
ASK1-dependent killing. Indeed, coexpression of Myc-FasD
and ASK1 caused synergistic killing within 24 hours (Fig. 4C).
This killing is quantitatively similar to that achieved by ASK1
plus Daxx (22), implying that the Daxx pathway is intact in
FasD. This result also suggests that the JNK pathway can
induce apoptosis quickly if sufficiently activated.
DISCUSSION
We have presented evidence that FADD and Daxx bind
independently to the death domain of Fas and identified FasD,
a mutation of the Fas cytoplasmic death domain that selec-
tively fails to bind FADD. These results support previous
functional data that FADD and Daxx activate distinct signaling
pathways downstream of Fas (21). The independent binding of
FADD and Daxx to Fas also suggests that the apoptotic defect
in FADD- or casp8-deficient cells and mice reflects the intrin-
sic signaling role of these molecules instead of possible struc-
tural roles in allowing Daxx to bind Fas. Mutations in the Fas
gene have been identified in several human lymphoprolifera-
tive disorders. Germ-line mutations in Fas were described in
kindreds aff licted with Autoimmune Lymphoproliferative
Syndrome (ALPS), a disease characterized by peripheral
accumulation of CD42CD82 T cells and autoantibody pro-
duction, leading to autoimmune symptoms (45, 46). More
recently, somatic mutations of Fas have been discovered in a
sizable fraction of multiple myelomas and non-Hodgkin’s
lymphomas (47, 48). In all of these diseases, heterozygous
point mutations in the Fas death domain with intact expression
of the wild-type allele are frequently encountered. These
findings have suggested that the Fas mutants encode dominant
interfering proteins, in particular by interfering with the
trimerization of wild-type death domains (45). In most cases,
the functional consequences of Fas mutation on downstream
signal transduction pathways are not understood. It is now
conceivable that in some cases, pathologic Fas mutations may
inactivate only FADD or Daxx signaling, and such differences
may impact disease presentation and progression. For exam-
ple, the inhibition of JNK activation downstream of Fas has
been shown to interfere with Fas-induced death in multiple
myeloma cells (49). Whether such specificity is reflected in the
disease-associated Fas mutations should be addressed in the
future.
FasD activated JNK as effectively as wild-type Fas (Fig. 3),
suggesting that JNK activation occurs independently of FADD
binding or caspase activation. These results are consistent with
the ability of Daxx to directly interact with and activate ASK1
(22). JNK activation also occurred normally in Casp82/2
mouse embryonic fibroblasts (MEFs) and HeLa cells stably
overexpressing the FADD death domain (32, 43). Casp82/2
MEFs were resistant to killing by Fas or TNF-a, but JNK
activation by either signal was unperturbed compared with
wild-type MEFs (32). Together these results provide strong
evidence that in some cells, Fas activates JNK by a FADD-
independent pathway. Because killing by FasD is slow, it
FIG. 2. Identification of FasD. (A) Schematic representation of
fusion proteins encompassing the cytoplasmic domain of murine Fas
(41). Boundaries of the death domain and FasD deletion are indicated.
(B) Binding of in vitro translated [35S]DaxxC and FADD(80–205) to
GST-fusion proteins. [35S]DaxxC (10 ml) and [35S]FADD(80–205) (0.2
ml) IVT reactions were added to all lanes. Positions of MW standards
(in kDa) are shown at right (Upper). Coomassie blue-stained GST
fusion proteins from the same gel is shown (Lower).
FIG. 3. (A) Expression of Myc-Fas and Myc-FasD. Human embry-
onic kidney 293 cells were transfected with the indicated plasmids,
immunoprecipitated with anti-Myc antibody conjugated to agarose
beads, and immunoblotted with anti-Myc antibody. (B) JNK activation
by Myc-Fas and Myc-FasD. Flag-tagged JNK1 (Flag-JNK) and the
indicated plasmids were cotransfected into 293 cells; 24 hours after
transfection, cells were treated with 0.5 mg/ml Jo2 antibody for 30 min
and assayed for JNK kinase activity. Upper, Phosphorylation of
GST-cJun. Lower, Expression of Flag-JNK. The data shown are
representative of three independent assays.
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suggests that the Daxx pathway is insufficient to compensate
completely for the loss of FADD-mediated caspase-8 activa-
tion to induce apoptosis. Although it is formally possible that
the apoptotic defect in FasD is caused by the inability to
associate with an unknown Fas-binding protein, the resistance
to Fas killing in FADD2/2 cells indicates that FADD is most
likely the relevant missing partner of FasD (31, 33). Sensitivity
to FADD-mediated apoptotsis can be modulated by the ex-
pression level of FLIP; therefore, a FADD-independent path-
way for JNK activation may underlie the ability of Fas to
stimulate cell proliferation in vivo (5). However, in Jurkat cells,
Fas-mediated JNK activation appears to depend on caspase
activation and caspase-8 in particular (28, 50). These differ-
ences may reflect tissue-specific regulation of Fas signaling
pathways. In this regard, reconstitution of lpr cells with Fas and
FasD may be an efficient approach to dissect Fas signaling in
primary cells. Preliminary results using retroviral transduction
of FasD into lpr T cells suggest that FADD binding to Fas is
required for T cell activation-induced cell death (L. van Parijs,
H.Y.C., and D.B., unpublished data).
Many questions remain regarding the role of JNK activation
in death receptor signaling. Results from FADD and caspase-8
knockout mice suggest that JNK activation is insufficient to
induce apoptosis; unfortunately, these studies mostly com-
pared the killing in the short period of time that is sufficient
for wild-type Fas to act. It is well known that the JNK pathway
can cause apoptosis if substantially activated (24), and the
results in the present study reinforce this idea. However,
because FasD killing occurred only with high levels of expres-
sion (such that the normal dependence on crosslinking anti-
body is abrogated), it is possible that this does not reflect the
physiologic condition. Whether the Daxx pathway is sufficient
for apoptosis in vivo in other cell types should be addressed in
future studies. The localization of Daxx may be partially or
even mostly nuclear, the significance of which is presently
unclear (51, 52). In many tissues in vivo, FasL expression
predominantly elicits an inflammatory response (8, 10). Re-
cently, Chen et al. (10) demonstrated that the proinflammatory
effect of FasL is mediated by Fas-induced p38 activation in
neutrophils; activated neutrophils can then kill FasL1 and
bystander cells in a nonspecific fashion. These results show a
physiologic role for Fas-mediated mitogen-activated protein
kinase activation and illustrate an indirect pathway of cell
death. Inhibition of the Daxx pathway may block the proin-
flammatory effect of FasL. Finally, whether the Daxx pathway
may be necessary for Fas-mediated apoptosis in vivo is not
addressed by the present study. Animals deficient in Daxx or
that express a Fas mutant unable to bind Daxx will be helpful
in addressing these questions.
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